Post-earnings recap
Reported
Tue, Apr 28, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
United Therapeutics reported a strong EPS, exceeding expectations, but the stock fell by over 5% in reaction. Investors may be concerned about the lack of revenue details and future guidance, which could indicate uncertainty about the company's performance going forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.55 | N/A | +21.60% |
| Revenue | N/A | N/A | N/A |
Management highlighted the strong EPS performance but did not offer detailed insights into revenue. They remain focused on future growth opportunities.
Management did not provide specific revenue figures for the quarter.
They expressed confidence in their product pipeline.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—